Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of HZN-825 in idiopathic pulmonary fibrosis
2021-001253-32Phase 2Active
- Sponsor
- Horizon Therapeutics
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fipaxalparant in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Change in FVC % predicted from Baseline to Week 52. Started Dec 2021; status: active.
02
Drugs
fipaxalparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2021-001253-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001253-32.